In ovarian cancer, research concentrates on leveraging TP53 mutations for treatment response assessment and identifying BRCA1/2 reversion mutations to guide PARP inhibitor therapy and unravel resistance mechanisms. This evidence concerns the gene BRCA1 and ovarian cancer.